Which has stronger earnings and valuation, OMCL or MASI?

Omnicell has higher earnings, but lower revenue than Masimo. Masimo is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.18B 1.61 $2.05M $0.44 95.20 Masimo $1.53B 6.13 -$151.50M -$10.54 N/A

Is OMCL or MASI more profitable?

Masimo has a net margin of 4.90% compared to Omnicell's net margin of 1.67%. Masimo's return on equity of 31.33% beat Omnicell's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 1.67% 4.00% 2.46% Masimo 4.90% 31.33% 13.93%

Does the media refer more to OMCL or MASI?

In the previous week, Omnicell had 1 more articles in the media than Masimo. MarketBeat recorded 3 mentions for Omnicell and 2 mentions for Masimo. Masimo's average media sentiment score of 1.16 beat Omnicell's score of 0.92 indicating that Masimo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Masimo 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMN or OMCL?

In the previous week, AMN Healthcare Services had 12 more articles in the media than Omnicell. MarketBeat recorded 15 mentions for AMN Healthcare Services and 3 mentions for Omnicell. Omnicell's average media sentiment score of 0.92 beat AMN Healthcare Services' score of 0.17 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Omnicell 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OMCL or WST?

In the previous week, West Pharmaceutical Services had 17 more articles in the media than Omnicell. MarketBeat recorded 20 mentions for West Pharmaceutical Services and 3 mentions for Omnicell. West Pharmaceutical Services' average media sentiment score of 1.09 beat Omnicell's score of 0.92 indicating that West Pharmaceutical Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive West Pharmaceutical Services 11 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OMCL or HSTM?

In the previous week, Omnicell and Omnicell both had 3 articles in the media. Omnicell's average media sentiment score of 0.92 beat HealthStream's score of 0.92 indicating that Omnicell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HealthStream 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer OMCL or MDRX?

Omnicell currently has a consensus price target of $59.86, indicating a potential upside of 42.89%. Given Omnicell's stronger consensus rating and higher possible upside, analysts clearly believe Omnicell is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omnicell 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, OMCL or MDRX?

Omnicell has higher earnings, but lower revenue than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.18B 1.61 $2.05M $0.44 95.20 Veradigm $1.53B 0.37 N/A N/A N/A

Is OMCL or MDRX more profitable?

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 1.67% 4.00% 2.46% Veradigm N/A N/A N/A

Does the media refer more to OMCL or MDRX?

In the previous week, Omnicell had 1 more articles in the media than Veradigm. MarketBeat recorded 3 mentions for Omnicell and 2 mentions for Veradigm. Omnicell's average media sentiment score of 0.92 beat Veradigm's score of 0.68 indicating that Omnicell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradigm 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Omnicell (OMCL) Competitors

$41.89 -0.02 (-0.05%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$42.48 +0.59 (+1.41%)

As of 08:20 AM Eastern

Compare

OMCL vs. MASI, AMN, WST, HSTM, and MDRX

Should you buy Omnicell stock or one of its competitors? MarketBeat compares Omnicell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Omnicell include Masimo (MASI), AMN Healthcare Services (AMN), West Pharmaceutical Services (WST), HealthStream (HSTM), and Veradigm (MDRX).

How does Omnicell compare to Masimo?

Omnicell (NASDAQ:OMCL) and Masimo (NASDAQ:MASI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 86.0% of Masimo shares are owned by institutional investors. 2.9% of Omnicell shares are owned by insiders. Comparatively, 9.7% of Masimo shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Masimo has a net margin of 4.90% compared to Omnicell's net margin of 1.67%. Masimo's return on equity of 31.33% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
Masimo	4.90%	31.33%	13.93%

Omnicell has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Masimo has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Omnicell presently has a consensus target price of $59.86, indicating a potential upside of 42.89%. Masimo has a consensus target price of $180.40, indicating a potential upside of 0.91%. Given Omnicell's stronger consensus rating and higher possible upside, equities research analysts plainly believe Omnicell is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Omnicell has higher earnings, but lower revenue than Masimo. Masimo is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.61	$2.05M	$0.44	95.20
Masimo	$1.53B	6.13	-$151.50M	-$10.54	N/A

In the previous week, Omnicell had 1 more articles in the media than Masimo. MarketBeat recorded 3 mentions for Omnicell and 2 mentions for Masimo. Masimo's average media sentiment score of 1.16 beat Omnicell's score of 0.92 indicating that Masimo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Masimo	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Omnicell beats Masimo on 9 of the 17 factors compared between the two stocks.

How does Omnicell compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

In the previous week, AMN Healthcare Services had 12 more articles in the media than Omnicell. MarketBeat recorded 15 mentions for AMN Healthcare Services and 3 mentions for Omnicell. Omnicell's average media sentiment score of 0.92 beat AMN Healthcare Services' score of 0.17 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AMN Healthcare Services presently has a consensus price target of $25.29, indicating a potential downside of 16.48%. Omnicell has a consensus price target of $59.86, indicating a potential upside of 42.89%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Omnicell has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.43	-$95.70M	-$0.87	N/A
Omnicell	$1.18B	1.61	$2.05M	$0.44	95.20

99.2% of AMN Healthcare Services shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 1.1% of AMN Healthcare Services shares are held by insiders. Comparatively, 2.9% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Omnicell has a net margin of 1.67% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
Omnicell	1.67%	4.00%	2.46%

AMN Healthcare Services has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Summary

Omnicell beats AMN Healthcare Services on 12 of the 17 factors compared between the two stocks.

How does Omnicell compare to West Pharmaceutical Services?

Omnicell (NASDAQ:OMCL) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, West Pharmaceutical Services had 17 more articles in the media than Omnicell. MarketBeat recorded 20 mentions for West Pharmaceutical Services and 3 mentions for Omnicell. West Pharmaceutical Services' average media sentiment score of 1.09 beat Omnicell's score of 0.92 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
West Pharmaceutical Services	11 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

West Pharmaceutical Services has higher revenue and earnings than Omnicell. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.61	$2.05M	$0.44	95.20
West Pharmaceutical Services	$3.07B	7.28	$493.70M	$7.48	42.33

Omnicell has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

Omnicell presently has a consensus price target of $59.86, suggesting a potential upside of 42.89%. West Pharmaceutical Services has a consensus price target of $331.91, suggesting a potential upside of 4.82%. Given Omnicell's stronger consensus rating and higher probable upside, research analysts clearly believe Omnicell is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
West Pharmaceutical Services	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.93

West Pharmaceutical Services has a net margin of 16.85% compared to Omnicell's net margin of 1.67%. West Pharmaceutical Services' return on equity of 19.03% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
West Pharmaceutical Services	16.85%	19.03%	14.06%

Summary

West Pharmaceutical Services beats Omnicell on 12 of the 17 factors compared between the two stocks.

How does Omnicell compare to HealthStream?

Omnicell (NASDAQ:OMCL) and HealthStream (NASDAQ:HSTM) are both small-cap health care technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Omnicell and Omnicell both had 3 articles in the media. Omnicell's average media sentiment score of 0.92 beat HealthStream's score of 0.92 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HealthStream	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.7% of Omnicell shares are held by institutional investors. Comparatively, 69.6% of HealthStream shares are held by institutional investors. 2.9% of Omnicell shares are held by company insiders. Comparatively, 20.4% of HealthStream shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

HealthStream has a net margin of 6.39% compared to Omnicell's net margin of 1.67%. HealthStream's return on equity of 6.47% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
HealthStream	6.39%	6.47%	4.44%

HealthStream has lower revenue, but higher earnings than Omnicell. HealthStream is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.61	$2.05M	$0.44	95.20
HealthStream	$304.06M	2.36	$18.34M	$0.67	36.63

Omnicell presently has a consensus target price of $59.86, indicating a potential upside of 42.89%. HealthStream has a consensus target price of $24.00, indicating a potential downside of 2.20%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than HealthStream.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
HealthStream	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Omnicell has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, HealthStream has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Summary

Omnicell beats HealthStream on 9 of the 16 factors compared between the two stocks.

How does Omnicell compare to Veradigm?

Omnicell (NASDAQ:OMCL) and Veradigm (NASDAQ:MDRX) are both small-cap health care technology companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Omnicell has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.61	$2.05M	$0.44	95.20
Veradigm	$1.53B	0.37	N/A	N/A	N/A

97.7% of Omnicell shares are held by institutional investors. 2.9% of Omnicell shares are held by company insiders. Comparatively, 2.3% of Veradigm shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Omnicell had 1 more articles in the media than Veradigm. MarketBeat recorded 3 mentions for Omnicell and 2 mentions for Veradigm. Omnicell's average media sentiment score of 0.92 beat Veradigm's score of 0.68 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradigm	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
Veradigm	N/A	N/A	N/A

Omnicell currently has a consensus price target of $59.86, indicating a potential upside of 42.89%. Given Omnicell's stronger consensus rating and higher possible upside, analysts clearly believe Omnicell is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Omnicell has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

Summary

Omnicell beats Veradigm on 14 of the 15 factors compared between the two stocks.

Get Omnicell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMCL vs. The Competition

Export

Metric	Omnicell	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.91B	$1.57B	$6.47B	$12.54B
Dividend Yield	N/A	N/A	2.69%	5.22%
P/E Ratio	95.21	77.62	22.12	24.18
Price / Sales	1.61	6.92	527.87	112.26
Price / Cash	15.15	22.87	41.34	57.13
Price / Book	1.53	4.77	9.94	6.72
Net Income	$2.05M	-$54.76M	$3.57B	$337.19M
7 Day Performance	-6.33%	-3.52%	-2.47%	-0.75%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	33.88%	-2.71%	26.55%	33.09%

Omnicell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMCL Omnicell	3.7228 of 5 stars	$41.89 0.0%	$59.86 +42.9%	+35.0%	$1.91B	$1.18B	95.21	3,580
MASI Masimo	1.5436 of 5 stars	$178.81 flat	$180.40 +0.9%	+9.1%	$9.36B	$1.53B	N/A	2,200
AMN AMN Healthcare Services	1.6245 of 5 stars	$27.65 0.0%	$25.29 -8.6%	+48.2%	$1.07B	$2.73B	N/A	2,664	Analyst Revision Gap Down
WST West Pharmaceutical Services	4.2259 of 5 stars	$316.86 +0.1%	$322.89 +1.9%	+50.2%	$22.35B	$3.07B	42.36	10,800	Positive News Analyst Upgrade
HSTM HealthStream	2.7414 of 5 stars	$23.81 flat	$24.00 +0.8%	-14.6%	$695.61M	$304.06M	35.54	1,160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMCL) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omnicell (OMCL) Competitors

OMCL vs. MASI, AMN, WST, HSTM, and MDRX

How does Omnicell compare to Masimo?

Summary

How does Omnicell compare to AMN Healthcare Services?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Summary

How does Omnicell compare to HealthStream?

Summary

How does Omnicell compare to Veradigm?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omnicell (OMCL) Competitors

OMCL vs. MASI, AMN, WST, HSTM, and MDRX

How does Omnicell compare to Masimo?

Do institutionals & insiders have more ownership in OMCL or MASI?

Is OMCL or MASI more profitable?

Which has more risk and volatility, OMCL or MASI?

Do analysts rate OMCL or MASI?

Which has stronger earnings and valuation, OMCL or MASI?

Does the media refer more to OMCL or MASI?

Summary

How does Omnicell compare to AMN Healthcare Services?

Does the media prefer AMN or OMCL?

Do analysts rate AMN or OMCL?

Which has better valuation and earnings, AMN or OMCL?

Do institutionals and insiders believe in AMN or OMCL?

Is AMN or OMCL more profitable?

Which has more risk & volatility, AMN or OMCL?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Do institutionals & insiders hold more shares of OMCL or WST?

Does the media refer more to OMCL or WST?

Which has stronger earnings & valuation, OMCL or WST?

Which has more risk and volatility, OMCL or WST?

Do analysts rate OMCL or WST?

Is OMCL or WST more profitable?

Summary

How does Omnicell compare to HealthStream?

Does the media refer more to OMCL or HSTM?

Do institutionals and insiders have more ownership in OMCL or HSTM?

Is OMCL or HSTM more profitable?

Which has higher valuation and earnings, OMCL or HSTM?

Do analysts rate OMCL or HSTM?

Which has more risk & volatility, OMCL or HSTM?

Summary

How does Omnicell compare to Veradigm?

Which has higher earnings and valuation, OMCL or MDRX?

Do institutionals & insiders believe in OMCL or MDRX?

Does the media refer more to OMCL or MDRX?

Is OMCL or MDRX more profitable?

Do analysts prefer OMCL or MDRX?

Which has more risk & volatility, OMCL or MDRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools